|
Gene: PPARA |
Gene summary for PPARA |
Gene summary. |
Gene information | Species | Human | Gene symbol | PPARA | Gene ID | 5465 |
Gene name | peroxisome proliferator activated receptor alpha | |
Gene Alias | NR1C1 | |
Cytomap | 22q13.31 | |
Gene Type | protein-coding | GO ID | GO:0000122 | UniProtAcc | F1D8S4 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
5465 | PPARA | HTA11_1938_2000001011 | Human | Colorectum | AD | 1.28e-02 | 5.09e-01 | -0.0811 |
5465 | PPARA | HTA11_347_2000001011 | Human | Colorectum | AD | 5.60e-08 | 6.08e-01 | -0.1954 |
5465 | PPARA | HTA11_411_2000001011 | Human | Colorectum | SER | 1.47e-05 | 8.07e-01 | -0.2602 |
5465 | PPARA | HTA11_83_2000001011 | Human | Colorectum | SER | 5.28e-04 | 5.73e-01 | -0.1526 |
5465 | PPARA | HTA11_696_2000001011 | Human | Colorectum | AD | 8.21e-06 | 5.75e-01 | -0.1464 |
5465 | PPARA | HTA11_1391_2000001011 | Human | Colorectum | AD | 1.55e-07 | 7.61e-01 | -0.059 |
5465 | PPARA | F007 | Human | Colorectum | FAP | 1.20e-08 | -5.08e-01 | 0.1176 |
5465 | PPARA | A002-C-010 | Human | Colorectum | FAP | 1.32e-04 | -2.43e-01 | 0.242 |
5465 | PPARA | A001-C-207 | Human | Colorectum | FAP | 2.92e-04 | -1.40e-01 | 0.1278 |
5465 | PPARA | A015-C-203 | Human | Colorectum | FAP | 2.22e-36 | -5.06e-01 | -0.1294 |
5465 | PPARA | A015-C-204 | Human | Colorectum | FAP | 1.00e-06 | -3.08e-01 | -0.0228 |
5465 | PPARA | A014-C-040 | Human | Colorectum | FAP | 4.60e-07 | -5.02e-01 | -0.1184 |
5465 | PPARA | A002-C-201 | Human | Colorectum | FAP | 2.19e-16 | -3.40e-01 | 0.0324 |
5465 | PPARA | A002-C-203 | Human | Colorectum | FAP | 1.38e-02 | -7.67e-02 | 0.2786 |
5465 | PPARA | A001-C-119 | Human | Colorectum | FAP | 1.83e-09 | -4.23e-01 | -0.1557 |
5465 | PPARA | A001-C-108 | Human | Colorectum | FAP | 5.05e-16 | -1.35e-01 | -0.0272 |
5465 | PPARA | A002-C-205 | Human | Colorectum | FAP | 1.26e-28 | -4.30e-01 | -0.1236 |
5465 | PPARA | A001-C-104 | Human | Colorectum | FAP | 9.29e-03 | 8.15e-03 | 0.0184 |
5465 | PPARA | A015-C-005 | Human | Colorectum | FAP | 1.51e-04 | -2.53e-01 | -0.0336 |
5465 | PPARA | A015-C-006 | Human | Colorectum | FAP | 4.37e-19 | -5.16e-01 | -0.0994 |
Page: 1 2 3 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0046034 | Colorectum | AD | ATP metabolic process | 142/3918 | 277/18723 | 2.64e-29 | 8.26e-26 | 142 |
GO:0006091 | Colorectum | AD | generation of precursor metabolites and energy | 209/3918 | 490/18723 | 3.17e-28 | 6.61e-25 | 209 |
GO:0016032 | Colorectum | AD | viral process | 168/3918 | 415/18723 | 4.67e-20 | 3.66e-17 | 168 |
GO:0009896 | Colorectum | AD | positive regulation of catabolic process | 180/3918 | 492/18723 | 4.33e-16 | 1.94e-13 | 180 |
GO:0009150 | Colorectum | AD | purine ribonucleotide metabolic process | 142/3918 | 368/18723 | 4.29e-15 | 1.17e-12 | 142 |
GO:0006163 | Colorectum | AD | purine nucleotide metabolic process | 149/3918 | 396/18723 | 1.08e-14 | 2.80e-12 | 149 |
GO:0072521 | Colorectum | AD | purine-containing compound metabolic process | 153/3918 | 416/18723 | 4.34e-14 | 1.01e-11 | 153 |
GO:0031331 | Colorectum | AD | positive regulation of cellular catabolic process | 156/3918 | 427/18723 | 4.68e-14 | 1.05e-11 | 156 |
GO:0009259 | Colorectum | AD | ribonucleotide metabolic process | 144/3918 | 385/18723 | 5.25e-14 | 1.13e-11 | 144 |
GO:0009895 | Colorectum | AD | negative regulation of catabolic process | 124/3918 | 320/18723 | 1.66e-13 | 3.35e-11 | 124 |
GO:0019693 | Colorectum | AD | ribose phosphate metabolic process | 145/3918 | 396/18723 | 3.01e-13 | 5.71e-11 | 145 |
GO:0009117 | Colorectum | AD | nucleotide metabolic process | 168/3918 | 489/18723 | 2.20e-12 | 3.36e-10 | 168 |
GO:0006753 | Colorectum | AD | nucleoside phosphate metabolic process | 169/3918 | 497/18723 | 4.99e-12 | 6.98e-10 | 169 |
GO:0019058 | Colorectum | AD | viral life cycle | 119/3918 | 317/18723 | 6.18e-12 | 8.23e-10 | 119 |
GO:0051098 | Colorectum | AD | regulation of binding | 126/3918 | 363/18723 | 6.01e-10 | 4.88e-08 | 126 |
GO:0009144 | Colorectum | AD | purine nucleoside triphosphate metabolic process | 43/3918 | 88/18723 | 5.05e-09 | 3.19e-07 | 43 |
GO:0009135 | Colorectum | AD | purine nucleoside diphosphate metabolic process | 47/3918 | 103/18723 | 1.61e-08 | 9.22e-07 | 47 |
GO:0009179 | Colorectum | AD | purine ribonucleoside diphosphate metabolic process | 47/3918 | 103/18723 | 1.61e-08 | 9.22e-07 | 47 |
GO:0006090 | Colorectum | AD | pyruvate metabolic process | 47/3918 | 106/18723 | 4.85e-08 | 2.55e-06 | 47 |
GO:0009185 | Colorectum | AD | ribonucleoside diphosphate metabolic process | 47/3918 | 106/18723 | 4.85e-08 | 2.55e-06 | 47 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa05415 | Colorectum | AD | Diabetic cardiomyopathy | 114/2092 | 203/8465 | 3.65e-22 | 3.06e-20 | 1.95e-20 | 114 |
hsa04932 | Colorectum | AD | Non-alcoholic fatty liver disease | 90/2092 | 155/8465 | 4.83e-19 | 1.80e-17 | 1.15e-17 | 90 |
hsa04922 | Colorectum | AD | Glucagon signaling pathway | 41/2092 | 107/8465 | 1.18e-03 | 7.75e-03 | 4.94e-03 | 41 |
hsa05160 | Colorectum | AD | Hepatitis C | 54/2092 | 157/8465 | 3.87e-03 | 1.96e-02 | 1.25e-02 | 54 |
hsa054151 | Colorectum | AD | Diabetic cardiomyopathy | 114/2092 | 203/8465 | 3.65e-22 | 3.06e-20 | 1.95e-20 | 114 |
hsa049321 | Colorectum | AD | Non-alcoholic fatty liver disease | 90/2092 | 155/8465 | 4.83e-19 | 1.80e-17 | 1.15e-17 | 90 |
hsa049221 | Colorectum | AD | Glucagon signaling pathway | 41/2092 | 107/8465 | 1.18e-03 | 7.75e-03 | 4.94e-03 | 41 |
hsa051601 | Colorectum | AD | Hepatitis C | 54/2092 | 157/8465 | 3.87e-03 | 1.96e-02 | 1.25e-02 | 54 |
hsa054152 | Colorectum | SER | Diabetic cardiomyopathy | 103/1580 | 203/8465 | 1.45e-25 | 1.61e-23 | 1.17e-23 | 103 |
hsa049322 | Colorectum | SER | Non-alcoholic fatty liver disease | 75/1580 | 155/8465 | 2.16e-17 | 5.99e-16 | 4.35e-16 | 75 |
hsa049222 | Colorectum | SER | Glucagon signaling pathway | 38/1580 | 107/8465 | 2.57e-05 | 3.28e-04 | 2.38e-04 | 38 |
hsa054153 | Colorectum | SER | Diabetic cardiomyopathy | 103/1580 | 203/8465 | 1.45e-25 | 1.61e-23 | 1.17e-23 | 103 |
hsa049323 | Colorectum | SER | Non-alcoholic fatty liver disease | 75/1580 | 155/8465 | 2.16e-17 | 5.99e-16 | 4.35e-16 | 75 |
hsa049223 | Colorectum | SER | Glucagon signaling pathway | 38/1580 | 107/8465 | 2.57e-05 | 3.28e-04 | 2.38e-04 | 38 |
hsa054158 | Colorectum | FAP | Diabetic cardiomyopathy | 70/1404 | 203/8465 | 2.62e-10 | 2.18e-08 | 1.33e-08 | 70 |
hsa049328 | Colorectum | FAP | Non-alcoholic fatty liver disease | 54/1404 | 155/8465 | 1.98e-08 | 6.20e-07 | 3.77e-07 | 54 |
hsa049226 | Colorectum | FAP | Glucagon signaling pathway | 32/1404 | 107/8465 | 4.08e-04 | 3.10e-03 | 1.89e-03 | 32 |
hsa049312 | Colorectum | FAP | Insulin resistance | 32/1404 | 108/8465 | 4.90e-04 | 3.56e-03 | 2.16e-03 | 32 |
hsa04024 | Colorectum | FAP | cAMP signaling pathway | 51/1404 | 225/8465 | 1.02e-02 | 3.68e-02 | 2.24e-02 | 51 |
hsa054159 | Colorectum | FAP | Diabetic cardiomyopathy | 70/1404 | 203/8465 | 2.62e-10 | 2.18e-08 | 1.33e-08 | 70 |
Page: 1 2 3 4 5 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PPARA | SNV | Missense_Mutation | novel | c.779C>T | p.Ala260Val | p.A260V | Q07869 | protein_coding | tolerated(0.47) | benign(0.089) | TCGA-44-7659-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
PPARA | SNV | Missense_Mutation | rs575811356 | c.113N>T | p.Ser38Leu | p.S38L | Q07869 | protein_coding | deleterious_low_confidence(0) | benign(0.344) | TCGA-L9-A7SV-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Chemotherapy | cisplatin | CR |
PPARA | SNV | Missense_Mutation | novel | c.430N>G | p.Lys144Glu | p.K144E | Q07869 | protein_coding | deleterious(0.01) | probably_damaging(0.988) | TCGA-90-7766-01 | Lung | lung squamous cell carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
PPARA | deletion | Frame_Shift_Del | c.50delG | p.Gly17AlafsTer3 | p.G17Afs*3 | Q07869 | protein_coding | TCGA-49-6743-01 | Lung | lung adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | cisplatin | SD | |||
PPARA | insertion | Frame_Shift_Ins | novel | c.1192_1193insA | p.Met400AsnfsTer105 | p.M400Nfs*105 | Q07869 | protein_coding | TCGA-55-8506-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
PPARA | SNV | Missense_Mutation | novel | c.129N>T | p.Glu43Asp | p.E43D | Q07869 | protein_coding | tolerated_low_confidence(0.84) | benign(0) | TCGA-D6-A74Q-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
PPARA | SNV | Missense_Mutation | rs549236046 | c.392N>A | p.Arg131Gln | p.R131Q | Q07869 | protein_coding | tolerated(0.3) | possibly_damaging(0.885) | TCGA-P3-A6T0-01 | Oral cavity | head & neck squamous cell carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
PPARA | SNV | Missense_Mutation | rs749814012 | c.316N>A | p.Gly106Arg | p.G106R | Q07869 | protein_coding | deleterious(0) | probably_damaging(0.967) | TCGA-EJ-8474-01 | Prostate | prostate adenocarcinoma | Male | >=65 | 8 | Unknown | Unknown | SD |
PPARA | SNV | Missense_Mutation | c.331G>T | p.Gly111Cys | p.G111C | Q07869 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-BR-4362-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
PPARA | SNV | Missense_Mutation | rs549236046 | c.392N>A | p.Arg131Gln | p.R131Q | Q07869 | protein_coding | tolerated(0.3) | possibly_damaging(0.885) | TCGA-BR-8680-01 | Stomach | stomach adenocarcinoma | Male | <65 | III/IV | Chemotherapy | oxaliplatin | CR |
Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5465 | PPARA | TRANSCRIPTION FACTOR, ENZYME, DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR | T091317 | T091317 | 20350005 | |
5465 | PPARA | TRANSCRIPTION FACTOR, ENZYME, DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR | simvastatin | SIMVASTATIN | 23930676,24598718,23252946 | |
5465 | PPARA | TRANSCRIPTION FACTOR, ENZYME, DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR | BMS-687453 | CHEMBL1089501 | 20218621 | |
5465 | PPARA | TRANSCRIPTION FACTOR, ENZYME, DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR | GTF505 | |||
5465 | PPARA | TRANSCRIPTION FACTOR, ENZYME, DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR | ZYH-1 | |||
5465 | PPARA | TRANSCRIPTION FACTOR, ENZYME, DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR | agonist | 135650110 | CLOFIBRATE | |
5465 | PPARA | TRANSCRIPTION FACTOR, ENZYME, DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR | GFT14 | |||
5465 | PPARA | TRANSCRIPTION FACTOR, ENZYME, DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR | agonist | 135650558 | LY-510929 | |
5465 | PPARA | TRANSCRIPTION FACTOR, ENZYME, DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR | OLEIC ACID | OLEIC ACID | ||
5465 | PPARA | TRANSCRIPTION FACTOR, ENZYME, DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR | CIPROFIBRATE | CIPROFIBRATE |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |